BNET Industries
Nabi Biopharmaceuticals (NABI) is in the Pharma Industry
- Profit
- Dec 29 2007
- $47.0M
- Market Cap
- Sep 04 2008
- $304.0M
Latest News and Analysis
Nabi Biopharmaceuticals Q2 2008 Earnings Call Transcript
Nabi Biopharmaceuticals NABI Q2 2008 Earnings Call
Nabi Biopharmaceuticals Q1 2008 Earnings Call Transcript
Nabi Biopharmaceuticals Q1 2008 Earnings Call Transcript
Nabi Biopharmaceuticals Q4 2007 Earnings Call Transcript
Nabi Biopharmaceuticals Q4 2007 Earnings Call Transcript
Additional Resources
Omrix Biopharmaceuticals, Inc. Q2 2008 Earnings Call Transcript
Omrix Biopharmaceuticals, Inc. OMRI Q2 2008 Earnings Call Transcript
Keryx Biopharmaceuticals, Inc. Q2 2008 Earnings Call Transcript
Keryx Biopharmaceuticals, Inc. KERX Q2 2008 Earnings Call Transcript
China Pharma Holdings? Q2 Shows Moderating Growth
ChinaBio Today submits: China Pharma Holdings, Inc. (CPHI.OB) reported that its Q2 revenues climbed 32% to $11.3 million. Net income was up by 21% at $4 million. While these numbers are moving in the right direction, the Q2 results are less impressive than the 60% revenue growth and 78%...
Biotech's New Blockbusters -- Oh, Really?
Biotech's New Blockbusters -- Oh, Really?20 to 30 Blockbusters of Biotech Exist NowInnovation in Pharmacology?Beginning in the 1970, biopharmaceuticals were being researched for conceptual production in those places once called academic institutions. The first biopharmaceutical ever was a synthetic insulin called Humulin made by Genetech in 1982. Later...
Express Scripts Fine Settles PBM Mess -- For Now
Express Scripts Fine Settles PBM Mess -- For NowPBMsPublished on discoverwhatyouthink.blogspot.comThe Amazement and the Price of Innovation: PBMsRecently, you may have heard or read in mass media sources about the issue of what are known as pharmacy benefit managers that have clients who are prescribed medications created by what...
Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Dr. Irene Ghobrial of the Dana-Farber Cancer Institute presents phase 2 results demonstrating the single agent clinical activity of perifosine in patients with relapsed / refractory Waldenstroms Macroglobulinemia
Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 at the American Society of Clinical Oncology Meeting in Chicago, Illinois
Phase 2 Results of Perifosine in the Treatment of Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia to be presented Tomorrow, Tuesday, June 3rd at 12:00pm in Room E450a
Keryx Biopharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
Keryx Biopharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
Accentia Transfers Listing to NASDAQ Capital Market
TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that the Company received approval from the NASDAQ Stock Market for the transfer of the listing of its common stock from the NASDAQ Global Market to the NASDAQ Capital Market. The Company's common stock will be transferred to the NASDAQ Capital...
Hatteras Announces Its Scientific Advisory Board - Genentech Founder, Herb Boyer, to Serve as Chair
DURHAM, N.C. -- Hatteras Venture Partners announced today the establishment of its Scientific Advisory Board SAB. The Board of internationally renowned scientists and industry experts is focused on helping Hatteras identify trends and opportunities in the fields of biopharmaceuticals, medical devices, diagnostics, and related areas of life science innovation.
Omrix Biopharmaceuticals Inc. Earnings Call Transcript
Omrix Biopharmaceuticals Inc. Earnings Call Transcript
Aceto Corporation Schedules Fiscal 2008 Third Quarter Financial Results News Release and Conference Call
LAKE SUCCESS, N.Y. -- Aceto Corporation (NASDAQ:ACET), a global leader in the sourcing, regulatory support, marketing and distribution of chemically derived pharmaceuticals, biopharmaceuticals, specialty chemicals and crop protection products, today announced that it will issue its financial results of operations for its 2008 fiscal third quarter and nine months ended...
RegeneRx Biopharmaceuticals, Inc. Updates Dial-In Number for Year End Conference Call
BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN), today reminded investors that a conference call will be held for interested parties on Wednesday, April 2, 2008 at 3:00 p.m. Eastern Time to discuss the results and its outlook for 2008. The call will be accessible by telephone and through the Internet....
RegeneRx Biopharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Results
Company to Host Year End Conference Call on April 2, 2008
Pall Corporation Unveils Technical Innovation Center in China for Life Sciences
EAST HILLS, N.Y. -- Pall Corporation (NYSE: PLL) today unveils its first Technical Innovation Center in China, Pall Filter Beijing Co., Ltd. and welcomes life sciences industry leaders and dignitaries to the grand opening event in Zhanjiang Hi-Tech Park in Shanghai. The Center, which incorporates a state-of-the-art filtration validation lab,...
OMRIX Biopharmaceuticals, Inc. Q4 2007 Earnings Call Transcript
OMRIX Biopharmaceuticals, Inc. Q4 2007 Earnings Call Transcript
NanoImaging Services Receives $1.5 Million in Venture Funding from Merck Capital Ventures
Funds to be Used for Expansion of Service Laboratory; NanoImaging Provides High-Resolution 3D Imaging of Large Molecule Biopharmaceuticals
- Next »
- page 1 of 1
- « Previous
Sort byClose
View Related Content by Tag Close
- Incorporated: 1969
- CEO: Dr. Raafat E.F. Fahim Ph.D.
Nabi Biopharmaceuticals is a biopharmaceutical company focused on the development of products that address medical needs in the areas of nicotine addiction as well as infectious disease. As of Dec 29 2007, Co.'s products in development were NicVAX® (Nicotine Conjugate Vaccine) and StaphVAX® (Staphylococcus aureus Vaccine). NicVAX is an investigational vaccine designed as an aid to smoking cessation, as well as an aid to prevent relapses, while StaphVAX is an investigational vaccine based on patented technology designed to prevent S.aureus infections including those infections caused by antibiotic-resistant strains of S.aureus.
Key Competitors
Nabi Biopharmaceuticals Company Info
Board of Directors
Dr. Geoffrey F. Cox Ph.D.
Non-Executive Chairman
Dr. Raafat E.F. Fahim Ph.D.
Mr. Jason M. Aryeh
Mr. Timothy P. Lynch
Mr. David L. Castaldi
Mr. Peter B. Davis
Mr. Richard A. Harvey Jr.
Dr. Leslie Hudson Ph.D.
Ms. Linda Jenckes
Mr. Stephen G. Sudovar
Contact Information
5800 Park of Commerce Boulevard, N.W.
Boca Raton, FL
561 989-5800
NAICS Code
Biological Product (except Diagnostic) Manufacturing: 325414
